The single published case series showing symptomatic improvement following intra-articular BPC-157 injection for knee pain provides preliminary support for this indication, though the small sample size, retrospective design, and lack of imaging or biomarker assessment limit conclusions
Regulatory bodies including the MHRA and European Medicines Agency (EMA) continue to monitor safety data, and current product information for GLP-1 agonists includes cholelithiasis and cholecystitis as recognised adverse reactions
Fox CK, Barrientos-Prez M, Bomberg EM, Dcruz J, Gies I, Harder-Lauridsen NM, et al
TL1A is emerging across rheum/IBD, broadening anti-inflammatory options
Hims & Hers is disrupting the healthcare industry, testing the limits of regulations to make it easier to buy popular drugs at lower prices